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Abstract
Objective—To report clinical and pathologic relationships with disease spread in endometrial 
cancer patients.
Methods—Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who 
were eligible to participate in a surgical pathological study to create a clinically annotated tissue 
biorepository to support translational and clinical research studies. All patients were to undergo a 
hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic 
lymphadenectomy. From 2003–2007, open eligibility enrollment was conducted, and from 2007–
2011, eligibility was restricted to enrich underrepresented patients or those at high risk.
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Results—This report details clinical pathological relationships associated with extra uterine 
disease spread of 5866 evaluable patients including those with endometrioid histology as well as 
papillary serous, clear cell and carcinosarcoma histologies. Review of unrestricted enrollment was 
constructed in an effort to capture a cross-section population representative of endometrial cancers 
seen by the GOG participating members. Evaluation of this group of patients suggested the more 
natural incidence of different surgical pathological findings as well as demographic information. 
The addition of 2151 patients enrolled during the restricted time interval allowed a total of 1630 
poor histotype patients available for further analysis. As expected, endometrioid (E) cancers 
represented the largest enrollment and particularly E grade 1 and 2 (G1 and 2) were more 
frequently confined to the uterus. Grade 3 (G3) endometrioid cancers as well as the poor histotype 
(papillary serous, clear cell and carcinosarcoma) had a much greater propensity for extant disease.
Conclusions—This study confirms the previously reported surgical pathological findings for 
endometrioid cancers but in addition, using a large database of papillary serous, clear cell and 
carcinosarcoma, surgical pathological findings substantiate the categorization of poor histotypes 
for these cancers.
Keywords
Surgical-pathology; Poor histotypes
1. Introduction
Corpus cancer is the most commonly diagnosed gynecological cancer in the industrialized 
world. In 2015, the American Cancer Society (ACS) estimated almost 55,000 new cases 
would be diagnosed in the US and over 10,000 would die from their disease [1]. Over the 
last several decades, the incidence of endometrial cancer has increased some 45%; however, 
the deaths from this cancer have more than tripled. Some have suggested that the increased 
incidence is due to the fact that a larger number of our population has reached an age in 
which this cancer is most frequently seen and are living longer. The reason for the increased 
number of women dying from their disease is unknown.
For many years, endometrial cancer was clinically staged. Several retrospective studies 
going back into the middle of the last century suggested a large margin of error between the 
clinical and actual extent of the disease; however, prospective studies done by the 
Gynecologic Oncology Group (GOG) in the 1970s and 1980s definitively identified the true 
extent of the disease which was considerably more advanced than clinically suspected even 
with stage I disease [2]. These studies led FIGO in 1986 to change the staging of 
endometrial cancer from a clinical designation to one that was surgically determined. 
Although surgical staging can definitively be diagnostic, it did raise many questions in 
regards to whether or not all endometrial cancer patients need to be surgically staged, was it 
therapeutic and was it definitive in guiding subsequent therapy.
Even though surgical staging added considerable information concerning an individual 
cancer, yet other unknown factors probably contributed to the individual’s eventual outcome. 
Today, it is recognized that a patient’s genetically characterized tumor may provide pertinent 
information to detail individual risk and response to therapy and is the basis of precision 
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medicine. Within gynecological malignancies, molecular characterizations of ovarian and 
endometrial cancer have been performed. In 2003, the GOG initiated a prospective surgical 
pathological study (GOG-210) to create a large biorepository annotated with clinical and 
epidemiological information from a population of surgically staged endometrial patients. 
The bank tissue and data could support genomic, proteomics and immunoassay studies for 
the purpose of class prediction and discovery in these cancers and to identify and validate 
molecular characteristics associated with a risk of recurrence, clinical and histological 
characteristics and epidemiological factors.
2. Materials and methods
GOG-210 is a molecular and surgical pathological staging study of endometrial carcinoma. 
The overall goal of this protocol is to improve outcome and quality of life for patients with 
endometrial cancer. This fundamental goal was the development of more accurate models of 
risk, identification of cancer targets for therapeutic intervention and utilization of individual 
treatment based upon molecular characteristics identified in tumor tissue, normal tissue 
and/or in reality accessible biological fluids like serum and urine. Objectives were to 
establish a repository of clinical specimens (tissue, urine, serum) with detailed clinical and 
epidemiological data from patients with surgically staged endometrial carcinoma. Utilizing 
genomic, proteomics and immunoassay results could hopefully identify and validate 
molecular characteristics associated with risk of endometrial cancer recurrence, clinical and 
histological characteristics and epidemiological factors. These studies would hopefully 
improve the accuracy and resolution of the risk assessment models for predicting 
endometrial cancer recurrence in combination with clinical, pathological and 
epidemiological factors. This data then could be used to identify these characteristics that 
would help prevent or treat endometrial cancer and expand our current understanding of the 
biology progression, metastasis and responsiveness of endometrial cancer.
GOG-210 was designated to create a clinically annotated tissue biorepository. Patients were 
eligible if they had uterine carcinoma (adenocarcinoma or carcinosarcoma) and were 
appropriate surgical candidates for hysterectomy and surgical staging. Following enrollment, 
patients completed an epidemiological questionnaire. From September 2002 to September 
2007, open eligibility enrollment was constructed in an effort to capture a cross-section 
population representative of endometrial cancer (EC) seen by GOG participating members. 
In 2007, after meeting initial enrollment and tissue goals, eligibility was restricted to enrich 
for previously under-represented patients or those at high risk. Restricted enrollment criteria 
includes non-endometrioid cancers or endometrioid cancers that were one or more of the 
following: G3, positive cervical biopsies, preoperative imaging suggestive of deep 
myometrial invasion, lymph node enlargement or extrauterine disease, non-Caucasian race, 
Hispanic ethnicity, and BMI below 25. The study completed total enrollment in December 
2011.
All patients were to have a hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic 
and para-aortic lymphadenectomy as well as collection of pelvic washings for cytology. 
Intraperitoneal biopsies were collected as indicated. Patients with stage IV intraabdominal 
disease that could not be debulked to <2 cm did not require a lymphadenectomy (LND). 
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“Adequacy” of the LND was determined by review of the operative and pathology reports 
and was measured by the presence of at least 10 lymph nodes including at least one node 
from each nodal basin. Patients were not eligible if they had had prior retroperitoneal 
surgery or had received prior pelvic or abdominal radiation. Central pathology review was 
initially to be performed on all cases. After review of the first 1236 cases, it was deemed 
unnecessary for patients with stage IA-IC and grade 1 and 2 (G1 and 2) endometrioid (E) 
adenosquamous and mucinous histology to have central pathology review due to the high 
rate of concurrence with the institutional pathologist. An extended central pathology review 
was conducted by a group of GYN pathologists for patients with grade 3E histology, E 
histology in stage IIA-IV and all non-endometrioid histologies. Staging was assigned using 
the FIGO 1988 classification system. Follow-up forms, including vital status on all 
postoperative cancer-related treatments, were completed at the time of the postoperative 
clinical visits and subsequent follow-up forms were completed every three months for the 
first two years, every six months for the next three years, and then yearly for the next five 
years. Data was abstracted from evaluation forms for all patients. Descriptive statistics of the 
patient population and clinical pathological data were provided.
The biorepository was created by collecting up to a total of 13 specimens obtained at various 
time-points. Preoperative serum and urine, frozen and fixed normal tissue, frozen and fixed 
primary tumor, postoperative serum and three-year follow-up serums were to be obtained on 
all patients. In patients who subsequently recurred, serum and frozen and fixed recurrent 
tumors were collected when possible. Samples were collected and prepared at each GOG 
institution and shipped to the GOG tissue bank (Columbus, Ohio) where they are housed and 
distributed back to investigation for approved translational research projects.
For descriptive purposes, type 1 cancers are endometrioid histology and type 2 (poor 
histotype) are papillary serous, clear cell and carcinosarcomas. Although not yet categorized 
“mixed” and “others”, they have surgical pathologic findings similar to the type 1 cancers.
3. Results
A total of 6124 patients were enrolled with 5866 being evaluable. During the initial 
unrestricted enrollment period, 3838 patients were enrolled, 123 were excluded, and 3715 
patients were evaluable. For the restricted category, 2286 patients were enrolled, 135 were 
excluded and 2151 patients were evaluable. A total of 41,450 specimens were collected and 
deposited in the cytology tissue bank.
During the unrestricted enrollment time, there were 3715 patients entered into this protocol 
(Table 1). The median age at enrollment was 63.1 years, with 90% of patients being 50 years 
of age or older and with the vast majority being presumed postmenopausal. The white race 
was represented by 89% of patients enrolled with African-Americans represented only by 
7.9%. When type 1 and 2 were evaluated in regards to race, 76.1% of Caucasians were type 
1 cancers and 23.9% were type 2. In contrast, only 46.5% of African-Americans had type 1 
cancers and 53.4% were type 2. As expected, over 80% of the women were overweight or 
obese. About three-fourths of the patients had a surgical stage I cancer as noted by the FIGO 
1988 staging. Almost three-fourths of the patients had an endometrioid histological type 
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with the largest number being grade 1. Serous carcinomas were represented by 11.4%, clear 
cell 3.5%, carcinosarcomas 4.1% and other 7.2%. Again, almost three-fourths of the patients 
had disease limited to the endometrium or inner one-half of the myometrium. Positive 
peritoneal cytology was present in 8.9%, adnexal involvement in 8.6%. Pelvic node 
metastasis (PNM) was noted in 9.8% and the aortic nodes involvement (PANM) was 5.1%. 
Lymph vascular space involvement (LVSI) was present in 22.7%. It was felt important to 
report separately the unrestricted population as this reflected more of the natural status of the 
patients who were entered into the protocol from the respective institutions.
As noted, after the initial enrollment and tissue goals were met, eligibility was restricted to 
enrich previously unrepresented patients or those at high risk. Subsequent tables will include 
both the unrestricted (3715) and the restricted (2151) patient population for a total of 5866 
patients. By combining the two, certain high-interest areas such as nodal metastasis were 
enriched. Serous carcinomas now represented 15.5% of the patient population, clear cell 
5.3% and carcinosarcoma at 6.6%. The number of women with positive peritoneal cytology 
increased from 8.9% to 11.3%. Pelvic node metastasis increased from 9.8% in the 
unrestricted group to 12.6% in the combined group and aortic metastasis from 5.1% to 7.2%. 
Lymph vascular space involvement increased from 22.7% to 26.0%. As previous studies 
have noted, as the grade became more poorly differentiated, the chances of deep invasion 
increased considerably (Table 2). In grade 1 endometrioid cancer, 16% had outer one-half or 
serosal involvement compared with 26% for grade 2 and 46% for grade 3. The poor 
histotypes also mirrored grade 3 endometrioid cancers. In the papillary serous group, 34% 
had outer one-half or serosal involvement, clear cell 33% and carcinosarcomas 44%.
Table 3 details the relationship of pelvic and para-aortic node metastasis with other risk 
factors. As the grade in the endometrial cancer becomes more poorly differentiated, pelvic 
node metastasis increases from 4% in grade 1 to 17.8% in grade 3 (G3) while para-aortic 
node metastasis increases from 2% to 9% respectively. Lymph node metastasis occurs to a 
greater degree with the poor histotypes. To a certain degree, G3 endometrioid cancers 
closely mirror the poor histotypes although the latter do have higher lymph node metastasis 
(LNM) rates. Serous lesions have pelvic node metastasis in 25% and para-aortic node 
metastasis in 17.5%, clear cell cancer rates are 20.1% and 12.4%, and carcinosarcomas have 
21.1% and 15.2% nodal metastasis respectively. Of interest is the fact that the mixed cancers 
mirror the higher rate of nodal metastasis as seen with G3 endometrioid and the poor 
histotypes. These lesions as well as the “others” are being further categorized by the GOG 
expert GYN pathology panel. As depth of myometrial invasion increases, the chances of 
lymph node metastasis (LNM) increase considerably. Only 2.6% of pelvic lymph node 
metastasis (PLNM) and 1.2% of para-aortic node metastasis (PANM) was present if only 
endometrium was involved, but increased to 31% and 20% respectively with outer one-half 
of the myometrium or serosa involved.
Other risk factors also are correlated to LNM. Those with negative peritoneal cytology had 
PNM of 10.5% and 6.1% PANM compared with 31.8% and 22.7% respectively if peritoneal 
cytology was positive. Lymph vascular space involvement if negative had 4.1% PNM and 
2.3% PANM compared with 37.5% and 23.8% respectively if LVSI was present.
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The relationship of positive pelvic nodes to positive para-aortic nodes in the total population 
is noted in Table 4. There were 662 patients with positive pelvic node metastasis of which 
327 also had metastasis to the para-aortic area. In addition, there were 86 patients with 
negative pelvic nodes and metastasis to the para-aortic area. When only the endometrioid 
cancers were considered, 151 (4.7%) had metastasis to the pelvic nodes with 94 (2.9%) also 
had PALN (Table 5). There were in addition 29 (0.9%) with negative PNM but PANM. 
Overall, 7.6% had PNM and 3.8% also had PANM. In evaluating the type 2 cancers (serous, 
clear cell and carcinosarcoma), PNM was 21.9% of which over one-half also had PANM 
(Table 6). In addition, there were 2.3% of the patients with negative PNM with PANM. 
Overall, 13.9% had PANM.
As expected, when grade of endometrioid cancers and depth of invasion were evaluated, the 
chances of PNM increased dramatically (Table 7). Grade 1 with endometrium-only involved 
had only 0.8% metastasis whereas involvement of the outer one-half of myometrium, 15.4% 
had PNM. The same relationship is present with G3 but to a greater degree (1.7% 
endometrium-only versus 29.1% with the outer one-half myometrial involvement). All of the 
type 2 cancers had a greater incidence of pelvic node metastasis than endometrioid types. 
This relationship was also present when evaluating PANM. The PANM is appreciable with 
type 2 cancers (25.9%–32.4%) (Table 8).
4. Discussion
This report details the surgical pathological findings of a large study of endometrial cancer, 
which is important in order to have precise information so that specific basic science data 
can be individually identified. Tumor heterogeneity is an important feature within 
endometrial cancer and its different cell types which demonstrate differences in greater 
signatures, frequency of disease spread, rates of response to therapy and outcome. We report 
here the largest prospective collected series of women with detailed surgical pathological 
findings and the collection of tissue, serum and urine that will allow detailed translational 
and clinical research studies.
The clinical findings confirm previous GOG surgical pathological findings of endometrial 
cancer. What this study adds to previous reports is a large number of poor histotype cancers 
that have been evaluated which has not been previously reported. As noted, the study was 
amended after an initial net goal of over 3000 women. An additional 2151 patients were 
enrolled which were restricted to those under-represented or those at high risk. The contrast 
between endometrioid, particularly grade 1 and 2, and the poor histotypes in regards to 
prognostic factors is stark.
What has been considered by some to be a “good” cancer, in fact has a wide spectrum of 
poor prognostic factors, depending somewhat on the histology of the disease. E-type, as 
expected, represents the largest number of patients in this study with almost three-fourths of 
the patients reported in the unrestricted enrollment. Almost two-thirds are G1 and 2 with G3 
present in <10%. Certainly, G1 and 2 represent a good prognosis as 84% and 74% 
respectively have less than one-half myometrial invasion compared with 55% of G3. PLNM 
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was 4% for G1 and 7.3% for G2, and 2.0% and 3.6% respectively for PANM. This is in 
contrast to G3 in which 17.8% had PNM and 9.0% had PANM.
When the so-called poor histotypes (type 2) cancers are evaluated, this group of patient 
represents a larger number than previously noted with 26.2% in the unrestricted enrollment; 
however, when total enrollment is considered, 2175 poor histotype patients were analyzed. 
These tumors tend to have a greater number of patients with >50% myometrial invasion (33–
44%) similar to the 46% seen in E3. PNM occurred in 21–25% of patients and PANM of 
15–17%. Extent of disease to a great degree determines overall survival and this will be 
reported in a subsequent publication.
With tripling of the deaths in corpus cancer over the last several decades, it appears that 
there are other factors that can determine prognosis. Why do some E1 based on known good 
prognostic surgical pathological factors still recur and succumb to their disease while those 
with E3 or type 2 cancers, despite poor prognostic factors, remain tumor-free? The answer 
goes to the heart of this study (GOG-210). By providing a resource for investigators of tissue 
and surgical pathological information, multiple translational research projects to date are 
ongoing to evaluate molecular and biomarkers based evaluation of tumor to ideally allow 
better selection for optimal management (precision medicine). Already there have been 30 
published or submitted manuscripts or abstracts.
A better understanding of the genomic information that may provide better assessment is 
illustrated by the data provided by The Cancer Genomic Atlas (TCGA) project, of which 
many specimens were contributed from GOG 210 [3]. The initial study classified 
endometrial cancer into four categories: POLE, ultra-mutated, microsatellite instability 
hyper mutated, copy-number low, and copy-number high. Subsequent studies have 
suggested that these categories may predict additional prognostic factors in addition to long-
known surgical pathological factors. These and other areas are what will be further evaluated 
using the GOG-210 well-defined patient population and tissue database.
One of the interesting factors which is apparent from this study is the fact that based on 
surgical pathological findings, E3 resembles the finding of type 2 cancers more so than E1 
and 2. In Bokhman’s designation of type I and II cancers, his review was presumably based 
on endometrioid cancers as papillary serous, clear cell and carcinosarcomas were not 
mentioned although poorly differentiated cancers were included [4–8]. Based on clinical as 
well as pathological features, there were poor prognostic (type 2) in E1 patients and good 
prognosis (type 1) with E3. More recently, type 1 has been categorized as E1–3 and type 2 
being what is considered poor histotypes; papillary serous, clear cell and carcinosarcoma. 
Maybe it is time to redefine type 1 and type 2 cancers based on current knowledge with 
additional refinement when genomic analysis has been completed.
References
1. American Cancer Society. Cancer Facts & Figures 2015. American Cancer Society; Atlanta: 2015. 
2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic 
spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987; 
60:2035–2041. [PubMed: 3652025] 
Creasman et al. Page 8
Gynecol Oncol. Author manuscript; available in PMC 2017 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
3. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. 
Nature. 2011; 474:609–615. [PubMed: 21720365] 
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15:10–17. 
[PubMed: 6822361] 
5. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary 
serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid 
corpus cancer. B J Cancer. 2006; 94:642–646.
6. Setiawan VW, Yang HP, Pike MC, McCann SE, et al. Type I and II endometrial cancers: have they 
different risk factors? J Clin Oncol. 2013; 31:2607–2618. [PubMed: 23733771] 
7. Chan JK, Loizz V, Youssef M, Osann K, Rutgers J, Vasilev SA, et al. Significance of comprehensive 
surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol. 
2003; 90:181–185. [PubMed: 12821361] 
8. Clement PB, Young R. Non-endometrioid carcinomas of the uterine corpus: a review of their 
pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004; 
11:117–142. [PubMed: 15096727] 
Creasman et al. Page 9
Gynecol Oncol. Author manuscript; available in PMC 2017 November 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HIGHLIGHTS
• The largest prospective surgical pathologic evaluation of endometrioid cancer
• The first surgical pathologic evaluation of Type 2 endometrial cancer
• Endometrial grade 3 cancers resemble findings of Type 2 cancers.
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